相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model
Suganthini Krishnan-Natesan et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry
David L. Horn et al.
CLINICAL INFECTIOUS DISEASES (2009)
Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2009)
Candida albicans RFX2 Encodes a DNA Binding Protein Involved in DNA Damage Responses, Morphogenesis, and Virulence
Binghua Hao et al.
EUKARYOTIC CELL (2009)
Activity of Contemporary Antifungal Agents, Including the Novel Echinocandin Anidulafungin, Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007)
Shawn A. Messer et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing Candida spp. by the CLSI M27-A2 Standard Method
Luis Ostrosky-Zeichner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Effect of inducible nitric oxide synthase on apoptosis in Candida-induced acute lung injury
Shigekuni Hosogi et al.
BIOMEDICAL RESEARCH-TOKYO (2008)
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2007)
Anidulafungin versus fluconazole for invasive candidiasis
Annette C. Reboli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment
James A. Dowell et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Anidulafungin: a new echinocandin for candidal infections
Polo de la Torre et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2007)
Epidemiology of invasive candidiasis: a persistent public health problem
M. A. Pfaller et al.
CLINICAL MICROBIOLOGY REVIEWS (2007)
Cardiac failure in C5-deficient A/J nfice after Candida albicans infection
Alaka Mullick et al.
INFECTION AND IMMUNITY (2006)
The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis
TE Zaoutis et al.
CLINICAL INFECTIOUS DISEASES (2005)
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole
MA Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2005)
Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction
MF Hebert et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Changing patterns and trends in systemic fungal infections
MD Richardson
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Mice with disseminated candidiasis die of progressive sepsis
B Spellberg et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Guidelines for treatment of candidiasis
PG Pappas et al.
CLINICAL INFECTIOUS DISEASES (2004)
Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study
H Wisplinghoff et al.
CLINICAL INFECTIOUS DISEASES (2004)
High dissemination and hepatotoxicity in rats infected with Candida albicans after stress exposure:: potential sensitization to liver damage
SG Correa et al.
INTERNATIONAL IMMUNOLOGY (2004)
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States
L Ostrosky-Zeichner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients
PG Pappas et al.
CLINICAL INFECTIOUS DISEASES (2003)
Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates.: Results from a six-year study (1996-2001)
F Marco et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2003)
A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects
JH Rex et al.
CLINICAL INFECTIOUS DISEASES (2003)
Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study
DJ Diekema et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2002)
Caspofungin: An echinocandin antifungal agent
EA Stone et al.
CLINICAL THERAPEUTICS (2002)
International surveillance of bloodstream infections due to Candida species:: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program
MA Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2001)
Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis
V Petraitis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species
CB Moore et al.
CLINICAL MICROBIOLOGY AND INFECTION (2001)
Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B
M Cuenca-Estrella et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2000)
分享论文
